The company said, “Core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related ...
MaxCyte Raises Q4 Guidance Driven by SPL Revenue MaxCyte sells electroporation tools and Strategic Platform License (SPLs). The net present value (NPV) of an SPL is $85 million, according to MaxCyte.
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERTâ„¢ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy ...
The deal came together about a year after a big leadership change. MaxCyte Inc. has made its first acquisition in its more than quarter-century of operation, about a year after its current CEO ...
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever MaxCyte, Inc, a life sciences company, discovers, develops, and ...
MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell and gene therapies. Their core ExPERT ATx, sTX, GTx, and VLx tools use ...